Evidence map›Paper›PMID 35255940›Full record

ArticleJournal of translational medicine2022

Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population.

John D Karalis, Lynn Y Yoon, Suntrea T G Hammer, Changjin Hong, Min Zhu, Ibrahim Nassour, Michelle R Ju, Shu Xiao, Esther C Castro-Dubon, Deepak Agrawal and 10 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

John D Karalis *Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-7601-5776
Lynn Y Yoon *Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Suntrea T G HammerDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Changjin HongDepartment of Artificial Intelligence and Informatics, Department of Immunology, Mayo Clinic, Jacksonville, FL, USA.
Min ZhuChildren's Research Institute, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ibrahim NassourDepartment of Surgery, University of Florida, Gainesville, FL, USA.
Michelle R JuDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shu XiaoChildren's Research Institute, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Esther C Castro-DubonDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Deepak AgrawalDepartment of Internal Medicine, University of Texas at Austin, Austin, TX, USA.
Jorge SuarezDepartment of Gastroenterology and Hepatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Scott I ReznikDepartment of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
John C MansourDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Patricio M PolancoDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Adam C YoppDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Herbert J ZehDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Tae Hyun HwangDepartment of Artificial Intelligence and Informatics, Department of Immunology, Mayo Clinic, Jacksonville, FL, USA.
Hao ZhuChildren's Research Institute, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Matthew R Porembka *Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sam C Wang *Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA. sam.wang@utsouthwestern.edu.ORCID http://orcid.org/0000-0003-3626-5273
The University of Texas Southwestern Medical Center · USMayo Clinic in Florida · USSouthwestern Medical Center · USThe University of Texas at Austin · USUniversity of Florida · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Improving hepatocellular carcinoma mouse modeling by understanding the malignant potential and biology of liver cell subpopulationsR01CA251928 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHU, HAO · 2020 to 2024
$2.7M
Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formationK08CA222611 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, SAM C. · 2018 to 2022
$804k
burroughs wellcome fund 1018897NCI NIH HHS K08 CA222611NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA251928
6 · The paper itself

Abstract

backgroundLenvatinib is a multitargeted tyrosine kinase inhibitor that is being tested in combination with immune checkpoint inhibitors to treat advanced gastric cancer; however, little data exists regarding the efficacy of lenvatinib monotherapy. Patient-derived xenografts (PDX) are established by engrafting human tumors into immunodeficient mice. The generation of PDXs may be hampered by growth of lymphomas. In this study, we compared the use of mice with different degrees of immunodeficiency to establish PDXs from a diverse cohort of Western gastric cancer patients. We then tested the efficacy of lenvatinib in this system.

methodsPDXs were established by implanting gastric cancer tissue into NOD.Cg-Prkdc

results23 PDX models were established from Black, non-Hispanic White, Hispanic, and Asian gastric cancer patients. The engraftment rate was 17% (23/139). Tumors implanted into NSG (16%; 18/115) and nude (21%; 5/24) mice had a similar engraftment rate. The rate of lymphoma formation in nude mice (0%; 0/24) was lower than in NSG mice (20%; 23/115; p < 0.05). PDXs derived using both strains maintained histologic and gene expression profiles across passages. Lenvatinib treatment (mean %Δv

conclusionsNude mice are a superior platform than NSG mice for generating PDXs from gastric cancer patients. Lenvatinib showed promising antitumor activity in PDXs established from a diverse Western patient population and warrants further investigation in gastric cancer.

Indexed as

Stomach NeoplasmsAnimalsHeterograftsHumansMiceMice, Inbred NODMice, NudePhenylurea CompoundsQuinolinesXenograft Model Antitumor AssayslenvatinibPhenylurea CompoundsQuinolinesGastric cancerLenvatinibNSG miceNude micePatient-derived xenograftPDX

Identifiers

PMID35255940
PMCPMC8900296
OpenAlexW4220769247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.